Company intelligence / Profile preview

Metro Medical

Worcester, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

MetroBiotech’s lead compound, MIB-626, is in multiple Phase 2 clinical trials for COVID-19, acute renal failure, and mild dementia. Extensive preclinical and Phase 2 data support the broad therapeutic potential of modulating NAD+. The company has developed oral dosage forms and scalable GMP manufacturing for its clinical programs.

Therapeutic areas: NephrologyNeurologyInfectious DiseasesRheumatologyRare DiseasesOphthalmology
Modalities: Small moleculeCrystallized precursor of nicotinamide adenine dinucleotide (NAD+)
Industry: Biotech

Beyond the preview

Go deeper on Metro Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metro Medical.

Explore the full profile